Beta

Spending
Congress
Stocks
Lobbying

Spending
Congress
Stocks
Lobbying

About Privacy Terms

© 2026 Adaptrex, LLC

About
Privacy
Terms

© 2026 Adaptrex, LLC

Spending
Congress
Stocks
Lobbying

MANNKIND CORPORATION — Lobbying — Receipts Report

LD-2 disclosure · 2nd Quarter - Report

MANNKIND CORPORATION

via THE KPM GROUP DC LLC

2nd Quarter (Apr 1 - June 30) · 2022Posted Jul 20, 2022Filing document ↗LDA record ↗

Income$30Kfee reported

Client

Name: MANNKIND CORPORATION
Description: Glucose management for types 1 and 2 diabetes
Location: California · United States of America

Registrant

Firm: THE KPM GROUP DC LLC
Description: lobby firm
Location: Washington, District of Columbia, United States of America

Lobbying activities

1 issue

Health Issues
Affordable Insulin Now Act
LobbyistsJACOB JACKSON · JOSEPH BALLARD
TargetedSENATE

Source

Source · Senate Office of Public Records — Lobbying Disclosure Act filings ↗.

Coverage gaps · LD-2 reports a single dollar figure per quarter on ONE basis — income (a fee) or expenses (self-filed spend), never both — so this page never combines them into one "spend" number.